BHST
NASDAQBioHarvest Sciences Inc.
Price$1.88-2.45 (-56.58%)
2026-04-212026-07-24
News · 26 weeks32+100%
2026-02-012026-07-26
Mix2090d
- SEC Filings11(55%)
- Other5(25%)
- Leadership2(10%)
- Earnings2(10%)
Latest news
25 items- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRBioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell SynthesisGrant will partially fund research to enable faster development, with a higher probability of success, of new plant-based compounds (precision botanics) for the benefit of BioHarvest's CDMO customers and partnersVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 15, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learnin
- PRBioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLCVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026.Presentation Details:Date/Time: Wednesday, July 22, 2026 at 10:00 a.m. ETPresenter: Zaki Rakib, Chief Executive OfficerFormat: Fireside Chat Location: VirtualOnline Access: https://digital.maximgrp.com/signupIn this virtual conference, Maxim Group Research Analysts sit dow
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRBioHarvest Sciences to Present at the 2026 BIO International ConventionVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details:Session: Company PresentationDate/Time: Wednesday, June 24, 11:45 AMLocation: Theater 3BioHarvest Sciences' presentation will showcase its proprietary Botanical Synthesis™ platform, which enables the production of plant-derived compounds with pharmaceutical-grade precision, consistency, and commercial scalability,
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRTate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener InnovationExpanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.The expanded collaboration
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRBioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateQuarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of AprilTwo-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 14, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced its first quarter 2026 financial results. The Company
- PRBioHarvest Sciences Appoints New Head of Business Development for its CDMO DivisionBusiness development appointment is aligned with securing long-term customers for development and manufacturing partnershipsVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest's contract development and m
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRBioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications- CDMO program advances to Stage 2 of development agreement valued at $1.125 million-Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals- In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Columbia and Rehovot, Israel---(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has completed Stage 1 under a multi-stage development agreement, successfully establi
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRBioHarvest Sciences to Report First Quarter 2026 Financial Results on May 14, 2026Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 30, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its first quarter 2026 financial results before the market opening on Thursday, May 14, 2026. The Company will also host a conference call and webcast at 8:00 a.m. U.S. Eastern Time to discuss the results and provide an update on business operations.First Quarter 2026 Earnings Call InformationDate: Thursday, May 14, 2026Time: 8:00 a.m. Eastern TimeWebcast: https://events.q4inc.com/attendee/387184352The earnings call webcast
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRBioHarvest Sciences Announces Strategic Leadership Transition with Dr. Zaki Rakib Assuming Role of Chief Executive Officer to Accelerate "Two-Lens" Growth StrategyIlan Sobel joins Board of Directors with focused mandate on D2C growth.Dr. Zaki Rakib, Co-Founder and Executive Chairman, assumes role of Chief Executive Officer, Integrating R&D, Manufacturing, and Operations under the CDMO.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - April 29, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology, today announced a strategic leadership transition designed to sharpen execution of its "two-lens strategy" across its direct-to-consumer ("D2C") business and its Contract Development and Manufacturing Organization ("CDMO") business.Dr. Zaki Rakib, the Company's
- SECSEC Form 40-F filed by BioHarvest Sciences Inc.40-F - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRBioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United StatesVINIA's leadership position in the market validates its superior arterial dilation and blood flow performance as well as BioHarvest's Botanical Synthesis platform technologyVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*.VINIA's leadership position is driven by its clinically demonstrated ability to increase arterial dilation, improving blood flow and enab
- SECSEC Form 6-K filed by BioHarvest Sciences Inc.6-K - BIOHARVEST SCIENCES INC. (0001723464) (Filer)
- PRBioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ:BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.Fourth Quarter and Full Year 2025 Earnings CallDate: Tuesday, March 31, 2026Time: 4:30 PM Eastern TimeWebcast link: https://events.q4inc.com/attendee/512060117The Earnin
BHST FAQ
3 questionsWhere does BHST stock trade?
BioHarvest Sciences Inc. (BHST) is listed on NASDAQ.What are analysts saying about BHST?
BioHarvest Sciences Inc. has had 3 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $1000.00 price target on 2026-02-19. Recent price targets range from $1000.00 to $1500.00.How can I track BHST on Quantisnow?
Quantisnow aggregates BioHarvest Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BHST to receive live email and push alerts on every new disclosure.